Federal ban on gender care for minors opens doctors to 25-year retroactive lawsuits.

What it does

This bill prohibits healthcare professionals, hospitals, and clinics from providing puberty blockers, sex hormones, or gender-affirming surgeries to minors under 18, defining these treatments as 'chemical or surgical mutilation.' It creates a federal private right of action allowing individuals and parents to sue providers for damages—including compensatory, non-economic, and punitive damages—for up to 25 years after the patient turns 18, with strict liability for violations and a broad jurisdictional hook based on interstate commerce.

Why we flagged it

The bill's core mechanism is a federal prohibition on gender-affirming medical treatments for minors, coupled with a private right of action that applies retroactively to treatments provided before enactment. This is not primarily a medical-safety or child-protection measure in the conventional sense—it is a categorical ban on a class of treatments, enforced through civil liability rather than regulatory oversight.

What the text implies

• Retroactive liability (Section 4) exposes healthcare providers to lawsuits for treatments performed before the bill's enactment, potentially decades after the fact, under standards that did not exist at the time of treatment. This creates legal jeopardy for conduct that was lawful and aligned with prevailing medical standards when performed.
• The 'clear and convincing evidence' standard for exceptions (Section 3) and the burden-shifting rule (Section 4) place the evidentiary weight on defendants to prove medical necessity, inverting the usual presumption that lawful medical practice is valid unless proven harmful.
• Interstate commerce jurisdiction (Section 3(b)) is extremely broad—any payment made 'in furtherance of' the treatment using any means affecting interstate commerce triggers federal jurisdiction, potentially capturing routine insurance claims, pharmacy transactions, or even telemedicine consultations.
• The definition of 'sex' (Section 2(7)) as 'immutable biological classification determined at conception' is a legislative statement of biological fact that contradicts the medical and scientific consensus on sex development and may create conflicts with other federal civil-rights statutes (Title IX, ADA) that reference sex or gender identity.
• Section 5(4) creates a 'limited deference' standard for pre-enactment conduct, allowing courts to second-guess medical standards of care that were in 'serious, scientific, and medical dispute'—a vague standard that invites litigation over what constitutes legitimate medical disagreement.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

The bill restricts medical autonomy and parental choice in healthcare decisions for minors, potentially blocking access to treatments some families and medical professionals consider medically necessary; however, it also creates legal recourse for individuals who later regret such treatments. The balance between protecting minors from irreversible medical decisions and preserving access to treatments endorsed by major medical organizations remains genuinely contested.

Who stands to gain

• litigation funders and plaintiff's attorneys (contingency-fee class actions)
• medical malpractice insurers (increased claims and premiums)

Named in the bill

health care professionals, hospitals, clinics, Chloe Cole, U.S. District Courts, FDA, state medical boards, pharmaceutical companies (BMY, GH, PFE, JNJ, DVA)

Where it stands

44 cosponsors: 44 Republicans.

• Sep 18, 2025 — Introduced · Congress.gov: “Introduced in House”
• Sep 18, 2025 — Referred to House Committee on Energy and Commerce · Congress.gov: “Referred to the House Committee on Energy and Commerce”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

4 lobbying clients named this bill on 6 disclosure filings across 2 quarters, Dec 2025 to Jun 2026. Those filings disclosed $489,908 in lobbying spend. A filing names 15 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 72% of bills with at least one filing.

Robert Onder, the sponsor, reported $438,000 in PAC receipts in the 2026 cycle.

• Human Rights Campaign — $439,908 on 2 filings
• Alliance Defending Freedom — $40,000 on 2 filings
• American Principles Project — $10,000 on 1 filing
• Family Research Council — $0 on 1 filing

Lobbying Disclosure Act filings through Jul 20, 2026. A filing shows who paid to lobby on a bill it names, not what changed.